Skip to main content

Table 2 Disease activity and TMJ clinical measures during 2-year follow-up in 15 adolescents with JIA and TMJ-arthritis receiving IACs

From: Efficacy and safety of intraarticular corticosteroid injections in adolescents with juvenile idiopathic arthritis in the temporomandibular joint: a Norwegian 2-year prospective multicenter pilot study

  Pre- injection (T0) 2-months FU (T1) 1-year FU (T2) 2-year FU (T3) p-value T0-T1
Median months after IACs 0 2.0 (1.8, 3.3) 12.0 (11.0, 13.0) 22.0 (22.0, 23.0)  
(1st, 3rd quartile) n = 15 n = 14 n = 15 n = 11  
Disease activity, no (%)**
 Active 15 (100) 7 (54) n = 13 10 (77) n = 13 6 (55)  
 Remission on medication 2 (15) n = 13 2 (15) n = 13 2 (18)  
 Remission off medication 4 (31) n = 13 1 (8) n = 13 3 (27)  
Medication ***
 No DMARDs, no (%) 6 (40) 5 (39) n = 13 4 (27) 3 (27) 0.317 a
 DMARDs (MTX), no (%) 3 (20) 2 (15) n = 13 3 (20) 3 (27)  
 Biologics comb, no (%) 6 (40) 6 (46) n = 13 8 (53) 5 (46)  
Disease activity measures
 JADAS10 15.8 (12.9, 49.1) n = 8 11.0 (6.0, 20.0) n = 7 12.5 (6.8, 14.5) n = 9 8.5 (3.3, 15.3) n = 4 0.273b
 No.of active joints 2.0 (1.0, 3.0) n = 14 0.0 (0.0, 2.0) n = 13 1.0 (0.0, 1.5) n = 13 0.0 (0.0, 1.0) n = 10 0.076b
 ESR (mm/h) 6.5 (3.5, 10.5) n = 12 6.0 (3.8, 11.0) n = 10 5.0 (3.0, 7.0) n = 11 5.5 (3.8, 7.3) n = 10 0.445b
 PRpainVAS 4.8 (3.3, 7.6) n = 10 3.5 (0.0, 5.8) n = 8 3.8 (1.6, 6.3) n = 10 1.5 (0.0, 4.5) n = 4 0.500b
 PRgloVAS 5.5 (3.3, 7.1) n = 10 3.5 (0.1, 5.8) n = 8 4.0 (1.6, 5.1) n = 10 0.5 (0.0, 4.0) n = 4 0.345b
 MDgloVAS 2.5 (1.6, 4.5) n = 12 0.5 (0.0, 4.0) n = 10 1.5 (0.1, 2.8) n = 12 0.0 (0.0, 1.0) n = 7 0.207b
TMJ activity measures
 Pain frequency 2.0 (0.0, 4.0) 1.0 (0.0, 2.0) n = 11 1.0 (0.0, 2.0) n = 13 0.0 (0.0, 2.0) n = 10 0.245b
 VAS pain intensity 3.0 (0.0, 6.5) n = 15 2.0 (0.0, 4.5) n = 11 2.0 (0.0, 3.5) n = 13 0.0 (0.0, 2.1) n = 10 0.292b
 VAS jaw function 3.0 (0.0, 4.3) n = 13 0.0 (0.0, 2.4) n = 10 0.0 (0.0, 0.0) n = 13 0.0 (0.0, 2.8) n = 9 0.201b
 Pain indexγ 6.0 (0.0, 13.0) n = 15 2.0 (0.0, 10.0) n = 11 2.0 (0.0, 8.5) n = 13 0.0 (0.0, 5.3) n = 10 0.263b
 MIO (mm) 44 (36, 48) n = 15 45 (43, 47) n = 13 45 (42, 49) n = 13 46 (45, 48) n = 11 0.045b
  1. Data are median (1st, 3rd quartiles) unless indicated otherwise. aMcNemar chi square test, bWilcoxon signed-rank test, *p ≤ 0.05 for statistical significance ** remission, status according to the ACR provisional remission criteria [39]***No DMARDs, Current us of NSAIDs and/or IACs; DMARDs, current use alone of MTX; Biologics comb, current use of Biologics alone or in combination with MTX; γ Pain index = Pain frequency last 2 weeks x Pain intensity last 2 weeks (VAS 0–10); JIA juvenile idiopathic arthritis, TMJ temporo-mandibular joint, LOM limited range on motion, VAS visual analogue scale, MTX methotrexate, DMARDs disease modifying antirheumatic drugs, PRpainVAS patient reported pain visual analogue scale, PRgloVAS Patient reported global assessment of well-being, MDgloVAS medical doctor global assessment of well-being, JADAS10 The composite juvenile arthritis 10-joint disease activity score, IACs intraarticular corticosteroid injections, ESR erythrocyte sedimentation rate, MIO maximal incisal opening, FU follow-up